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Abstract:[379/260] 
 
Background & Aims: We evaluated the efficacy and safety of obeticholic acid (OCA, α-
ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary 
cirrhosis (PBC) who had an inadequate response to ursodeoxycholic acid (UDCA) therapy. 
 
Methods: We performed a double-blind study of 165 patients with PBC (95% women) and 
levels of alkaline phosphatase (ALP) 1.5–10-fold the upper limit of normal. Patients were 
randomly assigned to groups given 10 mg, 25 mg, or 50 mg doses of OCA or placebo, once-daily 
for 3 months. Patients maintained their existing dose of UDCA throughout the study. The 
primary outcome was change in level of ALP from baseline (day 0) until the end of the study 
(day 85 or early termination). We also performed an open-label extension of the trial in which 78 
patients were enrolled and 61 completed the first year. 
 
Results: OCA was superior to placebo in achieving the primary endpoint. Subjects given OCA 
had statistically significant relative reductions in mean ALP from baseline to the end of the study 
(P<.0001 all OCA groups vs placebo). Levels of ALP decreased 21%−25% on average from 
baseline in the OCA groups and 3% in the placebo group. Sixty-nine percent (68/99) of patients 
given OCA had at least a 20% reduction in ALP compared to 8% (3/37) of patients given 
placebo (P<.0003). Among secondary endpoints, levels of γ-glutamyl transpeptidase decreased 
48%−63%, on average, among subjects given OCA vs a 7% decrease in the group given placebo; 
levels of alanine aminotransferase decreased 21%–35% on average among subjects given OCA 
vs none of the patients given placebo. Pruritus was the principal adverse event; incidence values 
in the OCA 10 mg, 25 mg, and 50 mg groups were 47% (not significantly different), 87% 
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(P<.0003), and 80% (P<.006), respectively, vs 50% in the placebo group. In the extension study, 
levels of ALP continued to decrease to a mean level of 202±11 U/L after 12 months vs 285±15 
U/L at baseline. 
 
Conclusion: Daily doses of OCA, ranging from 10 to 50 mg, significantly reduced levels of 
ALP, γ-glutamyl transpeptidase, and alanine aminotransferase, compared to placebo, in patients 
with PBC who had inadequate responses to UDCA. The incidence and severity of pruritus were 
lowest among patients who received 10 mg/day OCA. Biochemical responses to OCA were 
maintained in a 12 month open-label extension trial. ClinicalTrials.gov no: NCT00550862 
  
KEYWORDS: cholestasis, bile acids, FXR, dose study 
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Introduction 
 
Primary biliary cirrhosis (PBC) is a chronic, progressive autoimmune cholestatic liver disease 
which impacts quality of life and is associated with increased mortality.1 PBC is characterized by 
lymphocytic cholangitis and intralobular bile duct destruction leading to development of fibrosis, 
cirrhosis, and liver failure. Consistent with US and European guidelines, the current diagnosis of 
PBC is typically made on the basis of elevated alkaline phosphatase (ALP) values and positive 
anti-mitochondrial antibody (AMA) reactivity,2 and in keeping with this, the use of liver biopsy 
for diagnosis and staging has decreased significantly. PBC is increasingly diagnosed at earlier 
stages.3-5 The only approved drug to treat patients with PBC is ursodeoxycholic acid (UDCA), a 
hydrophilic, non-cytotoxic bile acid (BA) that is widely used.1, 6, 7 However, up to 40% of 
UDCA-treated patients have an inadequate biochemical response depending upon the criteria 
used, and such patients have significantly worse transplant-free survival rate than UDCA-
responsive patients.8-11 Accordingly, there is a significant medical need for new therapies for the 
treatment of PBC.12-19 
 
Obeticholic acid (OCA, INT-747) is a semi-synthetic analogue of the primary bile acid 
chenodeoxycholic acid (CDCA) which selectively activates the nuclear hormone receptor 
farnesoid X receptor (FXR).20,21 CDCA is the natural endogenous FXR agonist; the 6-alpha ethyl 
substitution on OCA imparts a nearly 100-fold greater FXR-activating potency.21 UDCA is an 
epimer of CDCA, but lacks meaningful FXR activity. OCA has shown anti-cholestatic, anti-
inflammatory and anti-fibrotic effects mediated by FXR activation in preclinical and clinical 
studies.20-23 Therefore, we reasoned that a more potent FXR agonist would have a positive 
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impact in patients with PBC. In this paper, we report findings from a 3-month, placebo-
controlled, dose-response trial of OCA added to UDCA in patients with PBC with an inadequate 
UDCA response. We also report results from patients on OCA treatment followed through 12 
months in an open-label extension trial. 
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Materials and Methods 
 
Patients. Patients, 18 to 75 years of age with PBC24, on a stable dose of UDCA for at least 6 
months prior to screening, were enrolled. PBC was diagnosed by at least 2 of 3 of: history of 
increased ALP levels for at least 6 months; positive AMA titer (>1:40 titer on 
immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear antibodies; and/or 
liver biopsy consistent with PBC. Patients were required to have a mean baseline ALP value 
between 1.5 and 10x the upper limit of normal range (ULN=117U/L for women; 129U/L for 
men). Key exclusion criteria were: elevated plasma AST or ALT levels >5x ULN; bilirubin >2x 
ULN; serum creatinine >1.5 mg/dL (133 µmol/L); use of colchicine, methotrexate, azathioprine, 
or systemic corticosteroids at any time during the 3 months prior to screening; history or 
presence of hepatic decompensation. Patients with other concomitant liver diseases, including 
autoimmune hepatitis overlap were also excluded. Patients maintained their existing dose of 
UDCA throughout the study. 
The study protocol and subsequent amendments were reviewed and approved by the 
appropriate Ethics Committees or Institutional Review Boards at each site. The trial was pre-
registered (www.clinicaltrials.gov; NCT00550862 and www.controlled-trials.com; 
ISRCTN67465025). The study protocol is available on request. All authors had access to 
complete datasets. GMH, LA, CS, TBJ, EC, OB and DS finalized analysis and data presentation. 
GMH, LA and DS had final responsibility to submit the manuscript after all authors reviewed 
and approved the manuscript. 
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Sample size. The study sample size was calculated in terms of effect size: 35 patients per group 
provided 80% power to detect an effect size of 0.70 which translates to approximately a 10% 
mean greater reduction in ALP levels between groups (see Supplementary Table 1).  
  
Randomization and masking. Eligible patients were randomly assigned (1:1:1:1) to one of four 
treatment groups for 85 days (3 months): OCA 10 mg, OCA 25 mg, OCA 50 mg or a matching 
placebo administered once daily. The computerized randomization schedule used a block size of 
4 at each center.  
 
Recruitment and the double-blind study phase occurred between November 2007 and May 2009. 
Study assessment visits were performed on Day 0 (randomization), 15, 29, 57, 85 (i.e. 3 months; 
End of Treatment [ET]). Patients had a follow up visit (off drug therapy) 14 days later. ALP and 
liver enzymes levels were determined at each visit by a central laboratory. Safety assessments 
included adverse events (AEs), pruritus, physical examinations, vital signs, clinical laboratory 
testing including lipids, and electrocardiograms. Blood samples for bile acids, fibroblast growth 
factor-19 (FGF19), C4, C-reactive protein and IgM assays were obtained at day 0 and 85 or at 
ET, if earlier.  
 
Open-label OCA therapy was offered to patients completing the double-blind portion of the 
study at 13 centers. These patients were dosed for at least an additional 12 months (unless they 
discontinued earlier). Patients were re-started on OCA 10-mg once-daily dosing or the dose 
assigned during the double-blind phase and allowed to titrate up or down at the discretion of the 
investigator based on individual ALP response and tolerability. Average daily OCA doses of <10 
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mg, typically to manage pruritus, were achieved by alternate or every third day dosing of a 10 
mg tablet.  
 
For the double-blind and open-label extension, pruritus was managed with dose reduction, 
medication interruption, use of other medications (e.g. antihistamines or bile acid sequestrants) 
or discontinuation, as deemed appropriate. 
 
Primary Efficacy Endpoint. The primary endpoint was the relative (percent) change in ALP 
values from baseline (Day 0) to end of study Day 85 in each of the OCA groups compared to 
placebo in the modified Intent-to-Treat (mITT) population.  
 
Efficacy Assessed by Published Response Criteria. The proportion of patients meeting the 
various previously published ‘non-response’ criteria at the start of the study were also evaluated 
(e.g. Paris I,8 II,9 Toronto criteria25, 26) in addition to two further criteria27 that also incorporated 
normal bilirubin levels. 
 
Secondary Endpoints. Secondary and exploratory endpoints were evaluated in the ITT 
pouplation and included changes in other liver enzymes (AST, ALT, GGT), conjugated bilirubin, 
and albumin values expressed as both absolute values, change from baseline and proportional 
changes. Other evaluations included assessment of lipids, free fatty acids, C-reactive protein and 
IgM. Changes were measured in blood serum concentrations of total endogenous BAs and the 
individual BAs:  UDCA, CDCA, cholic acid (CA), lithocholic acid (LCA), and deoxycholic acid 
(DCA). Changes in the BA precursor C4 (7α-hydroxy-4-cholesten-3-one) and FGF19, a marker 
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of FXR activation, were also assessed. Serum levels of unconjugated and glycine- or taurine-
conjugated OCA and other BAs were determined by LC-MS/MS.28 FGF19 concentrations were 
assayed using the solid-phase ELISA Quantikine FGF19 Immunoassay (R&D Systems, 
Minneapolis, MN). Serum C4 levels were determined by HPLC.29 
 
Statistical Analysis. Three analysis populations were evaluated. An Intent-to-treat (ITT) 
population (n=165) of randomized patients who received at least one dose of OCA. A modified 
ITT (mITT) population (n=161) of patients who received at least one dose of OCA and had at 
least one post-baseline ALP evaluation <7 days after their last dose of OCA, and a Completer 
population (n=136) of patients who had completed 85 days of treatment were also defined.  
A hierarchical testing strategy30 was used to account for multiple comparisons; statistical 
significance was evaluated at alpha = 0.05 for 10 mg vs. placebo, at alpha = 0.05 for 25 mg vs. 
placebo, then at alpha = 0.05 for 50 mg vs. placebo. The ‘last observation carried forward’ 
(LOCF) method was used for missing data. Primary analyses were performed on the mITT 
population. All secondary analyses were performed on the ITT dataset only. Additional ALP 
evaluations over time were analyzed for the Completer population. Pair-wise comparisons for 
OCA treatment groups vs. placebo changes used the 2-sided Wilcoxon-Mann-Whitney test at a 
5% significance level. Safety variables were summarized by treatment group with descriptive 
statistics. Disease severity criteria were assessed by Fisher’s exact test and the response analysis 
by χ2 test. 
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Results 
 
Study Patients. One hundred sixty-five patients from 41 North American and European centers 
were randomized in a 1:1:1:1 fashion to placebo or one of three once-daily doses of OCA, 10 
mg, 25 mg, and 50 mg (Supplementary Figure 1 for patient disposition). Nearly all enrolled 
patients were women (95%), Caucasian (96%), and had a positive AMA test (81%). Baseline 
demographics and clinical characteristics were similar at baseline between the groups (Table 1). 
The mean daily dose of UDCA at study entry was 15.6-16.3 mg/kg across all treatment groups 
(recommended dosing range 13-15 mg/kg/day). Most patients (82%) completed the study; 
pruritus was the principal cause for discontinuation (10%). The mITT population of 161 patients 
was evaluated for the primary endpoint. 
 
Primary Efficacy Endpoint. The primary endpoint in the study, relative (percent) change in 
mean ALP levels in the mITT group from day 0 to day 85 compared to placebo, was met across 
all OCA dose groups with statistical significance (P<.0001, Fig. 2A). Specifically, mean relative 
change in ALP from baseline from day 0 to day 85 was a decrease of 24% (95% CI -30% to -
18%), 25% (95% CI -30% to -20%), and 21% (95% CI -30% to -12%) for the 10 mg, 25 mg, and 
50 mg OCA groups, respectively, compared to a 3% decrease in the placebo group (95% CI -7% 
to +2%) (Fig. 2A). The results were virtually identical when the primary endpoint was applied to 
the ITT and Completer populations (P<.0001 for all OCA doses). The maximum decreases in 
ALP values in the Completer population (Fig. 3A, B) occurred on day 85 (3 months) for all OCA 
dose groups. However, statistically significant ALP reductions were observed as early as the two 
week study visit and the vast majority of the effect was seen at a month.  
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ALP completer analysis. There were also statistically significant ALP reductions of ≥10%, 20% 
and 40% in patients completing therapy in all OCA groups vs placebo (Fig. 1B). Specifically, 
87% (86/99) of OCA-treated patients completing therapy achieved at least a 10% ALP reduction, 
compared to 14% of placebo patients (5/37). Similarly, 69% (68/99) of OCA-treated patients 
showed at least a 20% reduction in ALP compared to 8% (3/37) of placebo-treated patients. ALP 
normalization was only achieved in 7% (7/99) of OCA-treated patients but in no placebo 
patients. 
 
Efficacy assessed by published response criteria.  The efficacy of OCA was also evaluated 
using five major published PBC biochemical algorithms which describe criteria shown to be 
predictive of adverse clinical outcomes (liver transplant or death):  Paris I,8 Paris II,9 Toronto I,25 
Toronto II,26 Mayo II27. While these criteria differ in their definition of biochemical response 
with respect to the key liver enzymes assessed and their threshold levels, all algorithms include 
criterion the level of which varies (range ≤1.5-3x ULN). Some algorithms employ other liver 
tests such as bilirubin (≤1 mg/dL), or AST (≤1.5-2x ULN).8, 9 Regardless of the algorithm used, 
OCA-treated patients always had higher rates of response than placebo-treated patients (Table 2).  
  
ALP assessment of open-label extension therapy. Following the double-blind portion of the 
study, 78 patients at select centers were enrolled into an open-label extension study. The 
biochemical results at 3, 6, 9 and 12 months are presented (Fig 2C,D). The biochemical 
improvements observed in the 3 month double-blind phase were maintained during the open-
label extension (12 months or more). Mean ALP for all three cohorts after 3 months in the OLE 
was 210±12 U/L and after 12 months had further decreased to 202±11 U/L. 
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Secondary Endpoints. 
Other Liver Biochemistry. Significant reductions in GGT (48 to 63%) and ALT (21 to 35%) 
values were observed for all OCA treatment groups compared to placebo from baseline to end of 
treatment (Table 3). Placebo-treated patients experienced essentially no change in these analytes 
from baseline to day 85. OCA was also associated with significant reductions in AST values (9 
to 17%) for all dose groups compared to placebo. Although mean conjugated bilirubin levels 
were in the normal range in all treatment groups at baseline, reductions in the median values 
were seen in the OCA treatment groups compared with a small increase in the placebo group 
(Table 3).  
 
Inflammatory Markers (Table 3). C-reactive protein (CRP) and IgM values also showed 
significant reductions from baseline at the end of the study with OCA treatment. Median CRP 
values decreased 21%, 42%, and 33% (p=.0595 for 10 mg, p=.0009 for 25 mg, and not 
significant for 50 mg compared to baseline values) in all three OCA treatment groups in 
comparison to a 10% increase for placebo. Median IgM values decreased by 14%, 21% and 18% 
at 10 mg, 25 mg, and 50 mg OCA (p=.0003 for 10 mg; p<.0001 for 25- and 50 mg compared to 
baseline), respectively, vs. a 19% increase in the placebo group. 
 
FGF19, C4, and Endogenous Bile Acids Levels analysis. Consistent with FXR agonist effects, 
significant increases in FGF19 from baseline to end of treatment were observed for 10 and 25 mg 
OCA dose groups compared to placebo (Fig. 3A). Significant reductions in C4 (Fig. 3B) and 
total endogenous BAs (Fig. 3C) were observed in all OCA dose groups, compared with an 
increase in the placebo group. Endogenous BA (i.e. BAs excluding UDCA and OCA) showed a 
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significant dose-related decrease compared with placebo. Mean values and SD of the individual 
and total BAs measured at baseline and at the end of the study (UDCA, CDCA, CA, LCA, DCA, 
OCA) are provided in Supplementary Table 4. At baseline, BA concentrations were similar for 
placebo and OCA-treated patients (Supplementary Table 5). The majority of total baseline BA 
concentration (63% to 65%) was UDCA (consistent with the mean 16 mg/kg dose being taken by 
the patients), followed by CDCA (11 to 15%), CA (11 to 12%) and DCA (5 to 7%). LCA 
comprised less than 1% of total BA concentrations. In treated patients OCA constituted less than 
2% of total plasma BAs. 
 
Adverse Events.  
Overall. 84% (32/38) of the placebo-treated and 96% (122/127) of OCA-treated patients 
experienced at least one AE (Supplementary Tables 2 and 3). Apart from pruritus, only mild or 
moderate nausea was reported more frequently in all three OCA groups than placebo. Severe 
AEs were primarily due to pruritus, and of 30/37 patients with severe AEs were pruritus-related.  
Pruritus. Although pruritus was no more common in the OCA 10 mg group compared to 
placebo, the severity appeared to be worse at this dose, and both the incidence and severity were 
worse in the two higher dosing groups. The incidence of pruritus in the OCA 10-mg, 25-mg and 
50-mg groups were 47% (not significant), 85% (P<.0003) and 80% (P<0.006) versus 50% in the 
placebo (Fig. 4A, Supplementary Table 3).  Severe pruritus was reported in 16% (6/38) of the 
patients in the 10-mg group, 24% (9/37) 25-mg group and 37% (15/41) 50-mg group of patients 
respectively. Overall, severe pruritus was less commonly reported during the open-label 
extension trial (Fig. 4B) and although 87% (68/78) of patients experienced some pruritus, only 
13% (10/78) discontinued OCA treatment as a result (Supplementary Tables 3 and 4). 
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Lipid Changes. Across all treatment groups patients at baseline had elevated levels of total 
cholesterol (median 218-239 mg/dL), LDL cholesterol (median 123-133 mg/dL), and HDL 
cholesterol (median 65-70 mg/dL) with normal to low levels of triglycerides (median 113-119 
mg/dL). A dose-related decrease in total cholesterol of 3%, 5% and 13% was noted for OCA 10-
mg, 25-mg, and 50-mg groups, respectively, mediated by a decrease in HDL levels (Table 3 and 
Supplementary Figure 4). Other lipids and triglycerides were not meaningfully changed. HDL 
levels remained stable following the early decline at each follow-up visit in OCA treated 
subjects.  
Other Adverse Events. Seven patients (4%; 7/165) experienced a SAE during the study including 
one patient in the placebo arm (dyspnea) and one patient in the OCA 25-mg arm (resection of 
non-malignant, pre-existent Warthin salivary gland tumor). Five patients in the OCA 50-mg 
group had SAEs: two had non-hepatic AEs (presumed gastroesophageal reflux disease, and 
angioedema/angina pectoris due to a food allergy which did not reoccur with continuing OCA 
treatment) while three patients had GI/hepatic AEs. One patient developed an upper gastro-
intestinal esophageal bleed approximately 1 week after therapy for pre-existing esophageal 
varices (that was not revealed to the investigator), 2 patients had significant rises in their 
bilirubin and aminotransferase levels that reverted to pre-study levels after OCA therapy was 
discontinued. OCA was restarted in one of these patients without a further rise in her bilirubin or 
aminotransferases. In total, 27 patients discontinued the study: 23 patients due to an AE, 3 
patients with elevated conjugated bilirubin, 1 patient with elevated AST/ALT; the majority of 
these patients (56%; 15/27) were receiving OCA at the highest dose of 50 mg (Supplementary 
Fig. 1). 
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Open-label Extension Over 1 Year. Seventy-eight patients were enrolled in the open-label 
protocol following completion of the double-blind trial; 61 patients (78%; 61/78) completed one 
year of dosing. Nearly all patients were re-started at an average daily OCA dose of ≤10 mg (75 
patients [96%; 75/78]), and patients were allowed to titrate OCA dosing at the discretion of the 
treating physician based on ALP response and tolerability. OCA daily doses ranged from 3 mg to 
60 mg daily throughout the trial. The mean final daily dose at 12 months was 20 mg. Although 
most patients (87%) complained of some pruritus during the open-label phase of the trial, the 
pruritus was generally less severe than in the double-blind phase (Fig. 4).  Nineteen patients 
(24%; 19/78) discontinued the open-label extension trial: pruritus (13%; 10/78); other AEs (5%; 
4/78; sleep-wake schedule disorder, rising blood glucose, left eye vitreous detachment, elevated 
conjugated bilirubin); consent withdrawal (3%, 2/78); major protocol violation (1%; 1/78); and 
other reasons (3%; 2/78).  
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Discussion 
This international, multicenter, placebo-controlled trial evaluated the utility of OCA 
across a range of doses for the treatment of PBC in patients with inadequate response to UDCA. 
OCA produced significant decreases in two biochemical, surrogate markers of PBC outcome, 
ALP and bilirubin. In addition, OCA may improve underlying immunological and inflammatory 
processes at play in PBC, as both CRP and IgM (the hallmark elevated immunoglobin in PBC) 
were significantly reduced. Pruritus, the most common symptom in PBC, was exacerbated with 
OCA treatment in a dose-related manner. 
 
The study data strongly suggest OCA primarily mediates its effects in PBC via FXR agonism. 
Physiologically a bile acid with FXR agonist properties would be expected to induce FGF19 
production from gut enterocytes, which would in turn mediate (via SHP induction) a decrease in 
endogenous bile acid synthesis, the post-prandial signal to decrease BA synthesis.31 Such effects 
were confirmed in this clinical study: serum FGF19 concentrations increased in a dose-related 
manner and both C4 (a bile acid precursor) and endogenous BA concentrations decreased. In 
contrast, UDCA is not an FXR agonist32 and is thought to mediate its beneficial effects in PBC 
by several mechanisms, including diluting toxic bile acids and promoting their excretion, 
providing biliary tract protection by up-regulating the biliary bicarbonate ‘umbrella’, and 
exerting immune-modulatory and anti-inflammatory effects.33-35 UDCA has low detergent 
properties requiring administration of large doses (13-15mg/kg/day) to be effective in PBC. 
Consequently, UDCA becomes the predominant BA comprising >60% of the BA pool. In 
contrast OCA, which comprised <2% of the serum BAs at the end of this study, appears to exert 
its effects at approximately 100-fold lower doses than UDCA. Considered together, these 
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complementary mechanisms likely explain the significant additional efficacy seen when OCA 
was added to UDCA in this study. OCA monotherapy efficacy in patients with PBC has been 
documented in a separate study,36 supporting the hypothesis that OCA effects are independent of 
concomitant UDCA dosing (Clinical Trials NCT00570765). 
 
With the use of UDCA for the treatment of PBC, the prognostic utility of alkaline phosphatase 
and other biochemical markers as surrogates for the ‘hard’ endpoints of death and liver 
transplantation continues to be evaluated.8-10 Recently, two groups analyzing large PBC cohorts 
have shown that lower ALP alone and combined with other biochemical markers is associated 
with better transplant free survival, both when assessed at discrete thresholds11 and as a continual 
variable.37 Our study shows that OCA produces significant reductions in ALP, GGT and to a 
lesser extent the aminotransferases. Bilirubin, which has long been shown to be predictive of 
clinical outcomes in PBC,38 decreased significantly in two of the OCA groups in the trial even 
though the vast majority of patients had mean bilirubin levels within the normal range. 
 
No clear differences were observed in biochemical endpoints across the 5-fold range of OCA 
doses studied strongly suggesting that the dose range studied in this trial was too high. This 
finding is somewhat surprising based on preclinical rodent studies that have consistently shown 
doses of 5-30 mg/kg are needed to elicit a therapeutic response in appropriate models.21 The 10-
mg dose of OCA represents approximately a 0.14 mg/kg dose in patients with PBC—nearly ten 
times lower than the effective doses in the animal studies. A likely explanation for these 
interspecies differences is that CDCA (upon which OCA is based) is the natural FXR ligand in 
man, but is not in rodents. 
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Pruritus was by far the most common AE in the study and was clearly OCA dose-related. While 
the exact mediators of cholestatic pruritus remain to be elucidated, two mechanisms have been 
proposed:  activation of the autotaxin pathway39 and activation of TGR5.40,41,42 Data from the 
present study are inconsistent with TGR5 induced pruritus; OCA is a weak TGR5 agonist and 
actually reduced levels of the endogenous human TGR5 agonist, DCA. Whether OCA activates 
the autotaxin pathway has yet to be determined. The incidence of pruritus in the 10-mg OCA 
group was no higher than that seen in the placebo patients (although the pruritus was more 
severe). Based on the dose-response induced pruritus observed in this study, we believe that 
doses of OCA lower than 10 mg will be better tolerated. A Phase 3 study of OCA is designed to 
address this issue (Clinical Trials NCT01473524). 
 
PBC patients with early disease have elevated HDL levels, however, altered risks of 
cardiovascular morbidity relative to the general population, have not been clearly 
demonstrated.10, 43 In this study, OCA treatment was associated with decreases in total and HDL 
cholesterol. Adverse cardiovascular events are unlikely to be a concern during the 3 month 
double blind or open label extension, however, longer studies are ongoing to explore potential 
adverse effects of chronic FXR activation, particularly on lipid homeostasis (Clinical Trials 
NCT01865812).  
 
The mechanism by which OCA contributes to lowering HDL has not been established in 
humans, but the observation is consistent with the OCA-mediated effects of FXR in animals and 
could be related to upregulation of reverse cholesterol transport through SR-B1 activation. 
Specifically, FXR knockout mice display hypercholesterolemia due to a marked increase in HDL 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 23
driven by downregulation of SR-B1, a key receptor for hepatic clearance of cholesterol from 
HDL.44 Similarly, partial or complete knockout of SR-B1 results in elevations in HDL with 
marked increases in mature, lipid-rich HDL.45 OCA has been shown in animal models to lower 
HDL driven by a decrease in mature, lipid-rich HDL.46 Moreover, atherogenic plaque formation 
was reduced by OCA in pro-atherogenic mice and led to a selective reduction of HDL2c or 
ApoAI in cynomolgus monkeys.46, 47 Nonetheless, the potential cardiovascular implication of 
these effects in humans needs to be established. Future studies will evaluate lipid profiles in 
patients with PBC to delineate HDL particle formation, maturation and clearance as well as 
macrophage cholesterol efflux before and after treatment with OCA (Clinical Trial 
NCT01865812). 
 
Limitations of the trial include limited duration of the study, the dose range evaluated and the 
need for further mechanistic studies focusing on pruritus and the lipid profile. Whilst 
biochemical surrogates are of clear value in PBC,8, 9, 25-27, 37 we acknowledge the challenges of 
applying any surrogate end point in the development and approval of new drugs.  
 
In conclusion, we present randomized controlled clinical trial data demonstrating 
biochemical efficacy of OCA, a FXR agonist, when given to patients with PBC with an 
inadequate response to UDCA therapy. Across all doses tested, biochemical efficacy of 
OCA was evident; based on the balance of efficacy and tolerability, in this study 10 mg 
once daily of OCA was the most effective dose, and has thus formed the basis for further 
studies of OCA in PBC. Evaluating the lower end of the dose response relationship in 
treatment of PBC is merited, as is a strategy of titrating the dose of OCA based on an 
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evaluation that includes biochemical markers and symptomatic response to low doses of the 
drug. Our trial therefore supports ongoing efforts to further evaluate the long term safety 
and clinical efficacy of OCA as a new therapy for patients with PBC.  
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Figure legends 
Figure 1. A. Mean (±SD) ALP relative change from baseline to end of study in the mITT 
(LOCF) population. P<.0001 pair-wise comparison for all treatment groups. B. Percent decrease 
in ALP values in the Completer population. Pairwise comparisons for 10%, 20% and 40% cut-
off respectively: 10mg P<.0001; P<.0001; P=.0031; 25mg P<.0001; P<.0001; P=.0272; 50mg 
P<0.000l for all cut-offs respectively. P value: Comparison of proportion of patients with a 10%, 
20%, 40% or complete response for OCA dose groups to placebo group using the Likelihood 
Ratio Chi-square test. 
Figure 2. OCA treatment decreases serum ALP levels in patients with PBC in the double-blind 
(DB) trial and the open-label extension. A. Decreases in ALP values during the double-blind 
phase were significant for all OCA dose groups vs. placebo at all the study day visits (P<.0001). 
Following OCA withdrawal on day 85, mean ALP values started to increase but two weeks later 
had not reached mean baseline ALP values and remained statistically lower compared with the 
placebo group. Absolute ALP values in the Completer population in the DB trial. P<.0001 for all 
OCA dose groups vs. placebo. B. Change in ALP values in the Completer population in the DB 
trial. P<.0001 for all OCA dose groups vs. placebo. C. Decreases in ALP values during the open-
label extension trial were significant for all OCA dose groups vs. placebo at all the study day 
visits (P<.0001). Change ALP values during the open-label extension trial for the completer 
population. P<.0001 for all OCA dose groups vs. placebo at all the study day visits. 
Figure 3. OCA treatment increases FGF19 and decreases C4 and endogenous bile acid plasma 
levels. Increased FGF19 (A), associated with decreased C4 (B) and endogenous bile acid (C) 
plasma levels in PBC patients following OCA treatment. Data are presented as median (line in 
middle of box), interquartile range (top and bottom of box), minimum and maximum (outliers 
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denoted by diamond). Statistical significance is based on the change from baseline to end of 
treatment. Following treatments with 10mg, 25mg, and 50mg of OCA, changes in FGF19 levels 
(P=.0007; P<.0001; P=.002), C4 (P=.0275; P<.0001; P<.0003) and BA (P=.0093; P<0.0001; 
P<.0001) were all respectively significant.  
Figure 4. Pruritus severity in PBC patients expressed as percent of patients with mild, moderate, 
or severe pruritus. A. Pruritus severity in the double-blind phase. B. Pruritus severity in the open-
label OCA therapy extension. 
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Table 1. Demographic and Baseline Characteristics of PBC Patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Placebo  
(N=38) 
OCA 10 mg 
(N=38) 
OCA 25 mg 
(N=48) 
OCA 50 mg 
(N=41) 
Sex (n[%])  
 
 
 
Male 2 (5%) 0 (0%) 3 (6%) 3 (7%) 
Women 36 (95%) 38 (100%) 45 (94%) 38 (93%) 
Age (years)  
 
Mean (SD) 54.8 (8.5) 55.6 (9.3) 55.9 (8.0) 54.0 (9.7) 
Range 36.0-72.0 37.0-71.0 35.0-69.0 37.0-71.0 
Body Weight (kg)  
 
Mean (SD) 74.3 (15.9) 73.6 (13.6) 72.7 (13.4) 70.9 (17.1) 
Range 44.0-107.6 50.0-99.2 45.4-101.3 46.2-116.0 
Body Mass Index (kg/m2)   
Mean (SD) 27.4 (5.2) 27.8 (4.7) 27.4 (5.1) 26.4 (6.2) 
Range 19.1-38.6 19.9-37.5 18.9-39.6 17.6-45.3 
Laboratory markers (mean; SD) 
ALP (U/L) 275.2 (102.7)  294.4 (149.4) 290.0 (123.6) 286.9 (106.2) 
Bilirubin (mg/dL) 0.2 (0.2) 0.2 (0.2) 0.2 (0.1) 0.3 (0.2) 
Albumin (g/dL) 4.2(0.3) 4(0.5) 4.1(0.4) 4.2(0.3) 
Platelets (103/µL) 281 (106) 272 (96) 275 (92) 244 (92) 
INR  1.00 (0.06) 1.01 (0.07) 1.02 (0.13) 1.05 (0.27) 
PBC Inclusion criteria (n[%]) 
History of Increased ALP  37 (97%) 36 (95%) 46 (96%) 39 (95%) 
Positive AMA Titer  33 (87%) 28 (74%) 40 (83%) 33 (80%) 
Liver Biopsy  33 (87%) 35 (92%) 43 (90%) 34 (83%) 
Total UDCA daily dose at study entry [mg/kg] 
Mean (SD) 15.9 (4.4) 15.9 (4.1) 15.6 (3.7) 16.3 (5.2) 
Range 8.8-26.9 7.2-25.4 8.4-24.7 6.6-35.0 
1st-3rd quartile 13 – 17.8 13.5 – 18.3 13 -17.2 13.5 – 17.6 
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Table 2. Biochemical Treatment Response Criteria: Baseline and Day 85 Response.  
 
 
Treatment groups/Criterion 
Placebo  
(n=38) 
OCA 10 mg  
(n=38) 
OCA 25 mg 
(n=48) 
OCA 50 mg   
(n=41) 
ALP ≤ 3x ULN or AST ≤ 2x ULN and tBili ≤ 1 mg/dL1 
 
Baseline (biochemical non-response; n) 5 11 10 10 
Day 85 (biochemical non-response; n) 5 7 3 5 
Day 85 % baseline non-responders with treatment effect 0 36% 70% 50% 
 
 
P=.24 P=.0256 P=.10 
ALP ≤ 1.5x ULN and AST ≤ 1.5x ULN and tBili ≤ 1 
mg/dL2  
Baseline (biochemical non-response; n) 34 46 40 
Day 85 (biochemical non-response; n) 34 22 30 25 
Day 85 % baseline non-responders with treatment effect 12% 35% 35% 35% 
  P=.0433 P=.0210 P=.0280 
ALP ≤ 1.67x ULN3 
 
Baseline (biochemical non-response; n) 32 30 39 35 
Day 85 (biochemical non-response; n) 28 17 22 19 
Day 85 % baseline non-responders with treatment effect 13% 43% 44% 43% 
  P=.0099 P=.0047 P=.0063 
ALP ≤ 1.76x ULN4 
 
Baseline (biochemical non-response; n) 29 28 38 30 
Day 85 (biochemical non-response; n) 24 17 20 14 
Day 85 % baseline non-responders with treatment effect 17% 39% 47% 50% 
  P=.0819 P=.0184 P=.0119 
ALP ≤ 1.67x ULN and tBili ≤ 1 mg/dL5 
 
Baseline (biochemical non-response; n) 33 30 39 37 
Day 85 (biochemical non-response; n) 28 18 22 21 
Day 85 % baseline non-responders with treatment effect 15% 40% 44% 41% 
  P=.0452 P=.0110 P=.0185 
ALP ≤ 1.67x ULN and tBili ≤ ULN6 
 
Baseline (biochemical non-response; n) 21 22 30 25 
Day 85 (biochemical non-response; n) 19 17 18 17 
Day 85 % baseline non-responders with treatment effect 10% 23% 40% 28% 
  
P=.41 P=.0248 P=.14 
Treatment groups were compared using Fisher’s exact test. 
Significant values are bolded.  
The evaluation of the treatment groups for various published algorithm (1Paris I; 2Paris II; 
3Toronto I; 4Toronto II) and 5,6deviations of Toronto I with the incorporation of normal bilirubin 
levels. 
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Table 3: Liver Chemistry, Immunologic Markers and Lipids 
 
 Placebo (N=38) OCA 10 mg (N=38) OCA 25 mg (N=48) OCA 50 mg (N=41) 
  Day 0 Day 85 Day 0 Day 85  P values Day 0 Day 85  P values Day 0 Day 85  P values 
Liver chemistry             
 ALT (U/L) 41 (28-53) 
40  
(26-63) 
45  
(30-60) 
27  
(22-41) <.0001 
39  
(30-59) 
24  
(19-38) <.0001 
40  
(33-70) 
27  
(21-43) 0.0018 
 AST (U/L) 38 (30-49) 
36  
(27-48) 
43  
(32-57) 
33  
(27-40) 0.0031 
39 
(30-47) 
29 
(24-42) 0.0026 
43  
(31-55) 
33  
(27-48) 0.0636 
 GGT (U/L) 142 (118-291) 
141 
(100-311) 
154 
(101-241) 
62  
(39-122) <.0001 
177 (92-
373) 
45 
 (24-124) <.0001 
178 
(118-312) 
55 
(30-140) <.0001 
 Conjugated 
 bilirubin 
 (mg/dL) 
0.15 
(0.10-0.25) 
0.19 
(0.10-0.20) 
0.20 
(0.10-0.30) 
0.19 
(0.10-0.30) 0.4117 
0.20 
(0.15-0.25) 
0.12 
(0.10-0.20) 0.0030 
0.25 
(0.15-0.30) 
0.20 
(0.10-0.30) 0.0218 
Immunologic            
 CRP (mg/L) 3.4  (1.6-7.9) 
5.5  
(1.4-8.1) 
5.5  
(3.1-9.5) 
4.7  
(2.8-6.4) 0.0595 
6.1  
(2.8-8.9) 
2.4  
(1.4-4.7) 0.0009 
3.7  
(1.5-6.3) 
2.1  
(1.0-6.4) 0.1674 
 IgM (mg/dL) 260 (170-440) 
260 
(170-450) 
390 
(290-520) 
350 
(240-490) 0.0003 
260  
(180-380) 
230  
(150-290) <.0001 
320  
(210-420) 
270  
(170-350) <.0001 
Lipids            
 Cholesterol 
 (mg/dL) 
239 
(201-258) 
246 
(204-268) 
218  
(190-251) 
206 
(179-244) 0.0055 
231  
(196-272) 
208  
(184-259) 0.0014 
239  
(193-258) 
199  
(160-230) <.0001 
 LDL (mg/dL) 133 (104-162) 
137 
(113-160) 
130  
(104-159) 
128 
(107-172) 0.4607 
133  
(105-157) 
139  
(108-165) 0.8893 
123  
(94-150) 
123  
(92-157) 0.6613 
 HDL (mg/dL) 70  (55-86) 
72  
(61-87) 65 (54-80) 
57  
(42-68) <.0001 
67  
(59-81) 
56  
(45-74) <.0001 
67 
(62-88) 
56  
(46-71) <.0001 
 Triglycerides 
 (mg/dL) 
119 
(101-154) 
106 
(85-137) 
113 
(81-148) 
108 
(86-139) 0.4030 
114  
(83-150) 97 (76-130) 0.8415 
115  
(76-143) 
93  
(73-134) 0.6242 
P values are for changes from baseline to end of treatment. 
Medians (quartiles 1st-3rd); Clinical laboratory reference range: ALT:  10-40 U/L; AST:  20-48 U/L; GGT:  0-30 U/L; Conjugated bilirubin:  0.2 
mg/dL; CRP:  < 0.80 mg/L; IgM:  54-222 mg/dL; Cholesterol:  70-232 mg/dL; LDL:  ≤162 mg/dL; HDL:  ≥35 mg/dL; Triglycerides:  ≤199 
mg/dL. 
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Legends for Supplementary Figures 
 
 
Supplementary Figure 1. Patient disposition. 
 
Supplementary Figure 2. Dose-titration effect of OCA therapy in the open-label extension. 
ALP values are presented as mean (± SD) % change from baseline after a 30-day pre-titration 
(gray bars) and 30-day post-titration (black bars) dosing. **P=0.01 for relative change from 
baseline compared to placebo. 
 
Supplementary Figure 3. Safety Population. Persistent biochemical response in PBC patients 
following OCA therapy in the open-label extension. Patients on OCA therapy in the OLE 
demonstrated sustained reduction compared to LTSE baseline in GGT (A), ALT (B) and AST 
(C) levels one year after treatment initiation. P<0.0001 (transaminases and GGT, all time-points) 
vs. time 0. Data are mean ± SD. 
 
Supplementary Figure 4. Mean absolute levels of HDL and LDL over time. Data are mean 
values for safety population. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3
Obeticholic Acid PBC Study Group  
 
Austria:  Prof Dr. Michael Trauner; Medical University Graz;  
Canada:  Dr. Alexander Aspinall; University of Calgary; Dr. Jenny Heathcote, Dr Gideon 
Hirschfield; University of Toronto; Dr. Andrew Mason; University of Alberta; Dr. Gerald 
Minuk; University of Manitoba; Dr. Catherine Vincent; University of Montreal (CHUM); 
France: Prof Christian Trepo; Hôpital de l’Hotel Dieu;  
Germany: Prof Dr. med Michael Manns, Dr. Kinan Rifai; Medical University Hospital PD Dr. 
Christian Rust; University of Munich Dr. Christoph Schramm; University Medical Center 
Hamburg-Eppendorf Prof Stefan Zeuzem, Johann Wolfgang Goethe University Hospital; 
Netherlands: Prof Ulrich Beuers, AMC; Henk R. van Buuren, Erasmus MC;  
Spain: Dr. Albert Parés Darnaculleta; Hospital Clinic Barcelona;  
United Kingdom: Prof Andrew Burroughs; Royal Free Hospital, London Dr. Roger Chapman; 
The John Radcliffe Hospital, Oxford Prof Peter Hayes; Edinburgh Royal Infirmary Prof James 
Neuberger, Dr. Dhiraj Tripathi; Queen Elizabeth Medical Center, Birmingham;  
United States: Dr. Bruce Bacon; St. Louis University Dr. Henry Bodenheimer, Jr.; Beth Israel 
Medical Center Dr. Stuart Gordon; Henry Ford Health System, Detroit Dr. Kris V. Kowdley; 
Virginia Mason Medical Center, Seattle Dr. Cynthia Levy; University of Florida Dr. Keith 
Lindor; Mayo Clinic Dr. Velimir Luketic; McGuire DVAMC Dr. Marlyn Mayo; UT 
Southwestern Medical Center Dr. Arthur McCullough; Cleveland Clinic Dr. Flavia de Oliveira 
Mendes; University of Miami Dr. Joseph Odin; Mt. Sinai School of Medicine Dr. Lawton Shick; 
Tufts Medical Center Dr. John M. Vierling; Baylor College of Medicine – St. Luke’s Episcopal 
Hospital.  
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Supplementary Table 1.  Study Power Calculations 
 
 
 Assumed numbers1 
(for sample size calculation) 
Observed numbers2 
10 mg 25 mg 50 mg 
Mean placebo -1% -3.5% -6% -2.6% -2.6% 2.6% 
Mean active -8% -13% -20% -23.7% -24.7% 21.0% 
Diff (Mean placebo – Mean active) 7% 10.5% 14% 21.1% 22.1% 18.4% 
SD 10% 15% 20% 15.4%3 15.8%3 21.6%3 
Effect size 0.7 0.7 0.7 1.37 1.40 0.85 
Power 80% 80% 80% 99% 99% 95% 
N (per group) 35 35 35 374 424 384 
1  Leading to an effect size of 0.7.  
The difference of means and SD are to be set for the estimation of the effect size, which is 
calculated as (meanactive – meanplacebo)/SD.  The listed mean values are examples which could 
results to the specified difference of means. 
2  
mITT; %-change from baseline. 
3
 Common SD calculated using observed SD’s from treatment groups. 
4
 Mean number of observed patients in both treatment groups. 
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Supplementary Table 2.  Summary of Treatment-Emergent Adverse Events by Treatment 
Group in the Double-blind Trial. 
 
 Treatment Group 
Total 
(N=165) 
Placebo  
(N=38) 
OCA  
10 mg  
(N=38) 
OCA  
25 mg  
(N=48) 
OCA  
50 mg  
(N=41) 
Subjects with any AEs 32 (84%) 34 (89%) 47 (98%) 41 (100%) 154 (93%) 
Subjects with treatment-related 
AE1 
22 (58%) 28 (74%) 45 (94%) 38 (93%) 133 (81%) 
Subjects with SAE 1 (3%) 0 (0%) 1 (2%) 5 (12%) 7 (4%) 
Subject deaths 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Subjects who withdrew due to 
an AE2 
1 (3%) 5 (13%) 5 (10%) 12 (29%) 23 (14%) 
AE reports (Entries) 96 101 152 198 547 
Mild 68 58 91 96 313 
Moderate 21 35 50 76 182 
Severe 7 8 11 26 52 
1
 Related adverse events include possibly or probably relationship. 
2 Three additional subjects discontinued the study due to elevated conjugated bilirubin. 
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Supplementary Table 3.  Incidence of All Adverse Events Occurring in ≥5% in Any Treatment 
Group During the Double-blind Trial. 
System Organ Class/ 
Preferred Term 
Treatment Group 
Placebo  
(N=38) 
OCA 10 mg  
(N=38) 
OCA 25 mg  
(N=48) 
OCA 50 mg  
(N=41) 
Subjects with any AEs 32 (84%) 34 (89%) 47 (98%) 41 (100%) 
Skin and subcutaneous 
tissue disorders 21 (55%) 19 (50%) 43 (90%) 36 (88%) 
Pruritus 19 (50%) 18 (47%) 41 (85%) 33 (80%) 
Rash 0 (0%) 0 (0%) 1 (2%) 2 (5%) 
Gastrointestinal disorders 10 (26%) 17 (45%) 17 (35%) 17 (41%) 
Abdominal distension 1 (3%) 2 (5%) 0 (0%) 4 (10%) 
Abdominal pain 2 (5%) 1 (3%) 2 (4%) 2  (5%) 
Abdominal pain upper 1 (3%) 0 (0%) 2 (4%) 2  (5%) 
Constipation 3 (8%) 3 (8%) 4 (8%) 3  (7%) 
Diarrhea 3 (8%) 3 (8%) 4 (8%) 3  (7%) 
Dyspepsia 0 (0%) 2 (5%) 2 (4%) 2  (5%) 
Nausea 1 (3%) 4 (11%) 3 (6%) 4 (10%) 
Vomiting 0 (0%) 0 (0%) 3 (6%) 0 (0%) 
General disorders and 
administration site 
conditions 7 (18%) 9 (24%) 8 (17%) 10 (24%) 
Chest pain 0 (0%) 0 (0%) 0 (0%) 2 (5%) 
Chills 0 (0%) 0 (0%) 2 (4%) 2 (5%) 
Fatigue 5 (13%) 7 (18%) 3 (6%) 5 (12%) 
Edema peripheral 0 (0%) 1 (3%) 1 (2%) 2 (5%) 
Pyrexia 0 (0%) 3 (8%) 0 (0%) 0 (0%) 
Infections and infestations 10 (26%) 8 (21%) 5 (10%) 11 (27%) 
Bronchitis 0 (0%) 2 (5%) 0 (0%) 0 (0%) 
Gastroenteritis viral 0 (0%) 0 (0%) 0 (0%) 2 (5%) 
Nasopharyngitis 1 (3%) 2 (5%) 1 (2%) 0 (0%) 
Sinusitis 2 (5%) 1 (3%) 0 (0%) 2 (5%) 
Tooth abscess 0 (0%) 2 (5%) 0 (0%) 1 (2%) 
Upper respiratory tract 
infection 2 (5%) 0 (0%) 1 (2%) 0 (0%) 
Urinary tract infection 3 (8%) 0 (0%) 0 (0%) 0 (0%) 
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System Organ Class/ 
Preferred Term 
Treatment Group 
Placebo  
(N=38) 
OCA 10 mg  
(N=38) 
OCA 25 mg  
(N=48) 
OCA 50 mg  
(N=41) 
Nervous system disorders 4 (11%) 4 (11%) 9 (19%) 8 (20%) 
Headache 4 (11%) 3 (8%) 5 (10%) 7 (17%) 
Hyperesthesia 0 (0%) 0 (0%) 0 (0%) 2 (5%) 
Respiratory, thoracic and 
mediastinal disorders 6 (16%) 3 (8%) 4 (8%) 11 (27%) 
Cough 1 (3%) 1 (3%) 0 (0%) 2 (5%) 
Dyspnea 2 (5%) 0 (0%) 0 (0%) 0 (0%) 
Oropharyngeal pain 1 (3%) 2 (5%) 4 (8%) 0 (0%) 
Epistaxis 0 (0) 0 (0) 0 (0) 4 (10) 
Musculoskeletal and 
connective tissue disorders 5 (13%) 5 (13%) 3 (6%) 6 (15%) 
Arthralgia 1 (3%) 2 (5%) 2 (4%) 0 (0%) 
Myalgia 2 (5%) 1 (3%) 0 (0%) 0 (0%) 
Pain in extremity 0 (0%) 0 (0%) 1 (2%) 4 (10%) 
Investigations 3 (8%) 3 (8%) 2 (4%) 2 (5%) 
Metabolism and nutrition 
disorders 1 (3%) 3 (8%) 1 (2%) 4 (10%) 
Hypokalemia 0 (0%) 0 (0%) 0 (0%) 2 (5%) 
Psychiatric disorders 1 (3%) 3 (8%) 3 (6%) 2 (5%) 
Insomnia 0 (0%) 2 (5%) 1 (2%) 2 (5%) 
Ear and labyrinth 
disorders 2 (5%) 1 (3%) 3 (6%) 2 (5%) 
Vertigo 2 (5%) 0 (0%) 0 (0%) 0 (0%) 
Eye disorders 1 (3%) 0 (0%) 4 (8%) 3 (7%) 
Dry eye 1 (3%) 0 (0%) 3 (6%) 2 (5%) 
Injury, poisoning and 
procedural complications 1 (3%) 1 (3%) 1 (2%) 2 (5%) 
Contusion 1 (3%) 0 (0%) 0 (0%) 2 (5%) 
Hepatobiliary disorders 0 (0%) 0 (0%) 0 (0%) 4 (10%) 
Renal and urinary 
disorders 1 (3%) 2 (5%) 1 (2%) 0 (0%) 
Reproductive system and 
breast disorders 2 (5%) 1 (3%) 1 (2%) 0 (0%) 
Cardiac disorders 2 (5%) 0 (0%) 0 (0%) 1 (2%) 
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System Organ Class/ 
Preferred Term 
Treatment Group 
Placebo  
(N=38) 
OCA 10 mg  
(N=38) 
OCA 25 mg  
(N=48) 
OCA 50 mg  
(N=41) 
Palpitations 2 (5%) 0 (0%) 0 (0%) 0 (0%) 
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Supplementary Table 4.  Bile Acid Levels at Baseline and Month 3 in the ITT Population 
During the Double-blind Trial.  
 Bile Acid Analytes (Mean [SD]) 
Treatment Group 
Placebo 
(N=32) 
OCA  
10 mg 
(N=32) 
OCA  
25 mg 
(N=42) 
OCA  
50 mg 
(N=34) 
Total Bile Acids (µmol/L)     
Baseline 18.8 (24.3) 33.9 (27.0) 28.4 (30.5) 37.8 (56.2) 
Month 3 23.2 (25.5) 30.6 (42.9) 24.1 (35.8) 72.6 (142.2) 
Mean Change from Baseline to Month 
3 0.53 (19.2) -4.5 (34.3) -3.0 (29.9) 33.5 (153.2)  
Median Change from Baseline to 
Month 3 -1.27  -5.95 -4.36 -4.17 
P values1 N/A 0.1549 0.1946 0.2903 
Total UDCA (µmol/L)  
  
Baseline 12.4 (15.6) 22.9 (20.0) 18.4 (19.9) 21.8 (30.7) 
Month 3 14.4 (15.0) 20.8 (31.5) 17.8 (21.9) 47.2 (87.8) 
Mean Change from Baseline to Month 
3 -0.08 (12.9) -2.32 (27.6) -0.07 (20.4) 24.0 (98.6) 
Median Change from Baseline to 
Month 3 -0.72 -2.55 -0.23 -1.96 
P values1 N/A 0.2381 0.7662 0.6408 
Total CDCA (µmol/L)   
 
 
Baseline 2.40 (3.75) 4.71 (4.13) 4.22 (5.46) 7.21 (14.65) 
Month 3 3.53 (4.51) 4.96 (7.67) 2.54 (5.15) 15.81 (37.95) 
Mean Change from Baseline to Month 
3 0.34 (3.20) 0.13 (4.62) -1.35 (4.09) 9.01 (37.01) 
Median Change from Baseline to 
Month 3 0.194 -0.736 -0.564 -0.898 
P values1 N/A 0.0542 0.0005 0.0189 
Total CA (µmol/L)     
Baseline 2.46 (3.64) 4.20 (4.30) 3.91 (5.87) 6.21 (11.96) 
Month 3 3.46 (5.34) 3.13 (6.18) 2.88 (10.80) 6.54 (16.31) 
Mean Change from Baseline to Month 
3 0.45 (3.26) -1.70 (4.66) -0.79 (8.24) 0.26 (17.23) 
Median Change from Baseline to 
Month 3 0.04 -0.68 -1.09 -1.00 
P values1 N/A 0.0030 0.0003 0.0044 
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 Bile Acid Analytes (Mean [SD]) 
Treatment Group 
Placebo 
(N=32) 
OCA  
10 mg 
(N=32) 
OCA  
25 mg 
(N=42) 
OCA  
50 mg 
(N=34) 
Total DCA (µmol/L)     
Baseline 1.27 (2.35) 1.81 (1.76) 1.65 (2.07) 2.33 (2.59) 
Month 3 1.60 (1.99) 1.10 (2.44) 0.36 (0.71) 1.28 (2.99) 
Mean Change from Baseline to Month 
3 -0.13 (1.70) -0.87 (1.98) -1.16 (1.66) -1.25 (4.22) 
Median Change from Baseline to 
Month 3 0.000 -0.31 -0.64 -1.02 
P values1 N/A 0.0021 <0.0001 <0.0001 
Total LCA (µmol/L)    
 
Baseline 0.194 
(0.320) 0.282 (0.363) 0.227 (0.398) 0.305 (0.445) 
Month 3 0.196 
(0.291) 0.321 (0.492) 0.167 (0.226) 0.305 (0.396) 
Mean Change from Baseline to Month 
3 
-0.034 
(0.185) 0.001 (0.326) 
-0.030 
(0.222) 
-0.055 
(0.529) 
Median Change from Baseline to 
Month 3 0.000 0.000 -0.021 0.000 
P values1 N/A 0.3782 0.3245 0.6839 
Total Endogenous Bile Acids 
(µmol/L)  
   
Baseline 6.35 (9.54) 11.0 (9.07) 10.0 (12.9) 16.0 (28.3) 
Month 3 8.80 (11.6) 9.52 (14.9) 5.95 (15.6) 23.9 (54.4) 
Mean Change from Baseline to Month 
3 0.6 (7.6) 
-2.4 (9.8) -3.3 (12.0) 8.0 (54.4) 
Median Change from Baseline to 
Month 3 0.0 
-2.3 -3.1 -3.7 
P values1 N/A 0.0108 0.0001 0.0071 
Total OCA (µmol/L) 
 
  
 
Baseline 0.000 0.000 0.000 0.003 (0.018) 
Month 3 0.000 0.252 (0.410) 0.371 (0.525) 1.552 (5.202) 
1P-values: Comparison of OCA dose group to placebo group using Wilcoxon-Mann-Whitney test. 
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Supplementary Table 5.  Mean Relative Proportion of Individual Bile Acids to Total Bile Acid 
Concentration at Baseline and Month 3 in the ITT Population During the Double-blind Trial.  
Laboratory Analytes 
(Mean [SD])/Time Point) 
Treatment Group 
Placebo 
(N=38) 
OCA 10 mg 
(N=38) 
OCA 25 mg 
(N=48) 
OCA 50 mg 
(N=41) 
Total UDCA   
  
Baseline 0.654 0.632 0.641 0.630 
Month 3 0.634 0.685 0.794 0.752 
Total CDCA     
Baseline 0.106 0.145 0.121 0.144 
Month 3 0.133 0.140 0.069 0.092 
Total CA     
Baseline 0.118 0.115 0.109 0.119 
Month 3 0.112 0.070 0.051 0.056 
Total DCA     
Baseline 0.051 0.051 0.069 0.051 
Month 3 0.063 0.019 0.003 0.009 
Total LCA     
Baseline 0.000 0.000 0.004 0.000 
Month 3 0.003 0.000 0.002 0.009 
Total OCA     
Month 3 N/A 0.014 0.013 0.018 
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Supplementary Table 6.  Missing Data From the Double-blind Trial. 
 
Number of Subjects Analysis 
by Time point 
FOR:  ALP, ALT, AST, 
GGT, Conj. Bilirubin, 
cholesterol, LDL, HDL and 
TG 
Treatment Group 
Total 
(N=165) Placebo (N=38) 
OCA 
10 mg  
(N=38) 
OCA 
25 mg  
(N=48) 
OCA 
50 mg 
(N=41) 
Baseline 38 38 48 41 165 
Day 15 36 38 46 33 153 (93%) 
Day 29 37 35 43 27 142 (86%) 
Day 57 36 33 41 26 136 (82%) 
Day 85/ET 38 38 48 40 164 (99%) 
Day 99 38 35 43 34 150 (91%) 
Number of Subjects Analysis 
by Time point 
FOR:  CRP 
Treatment Group 
Placebo 
(N=38) 
OCA 
10 mg  
(N=38) 
OCA 
25 mg  
(N=48) 
OCA 
50 mg 
(N=41) 
Baseline 32 36 41 35 
Day 85/ET 31 28 36 30 
Change from baseline 28 (74%) 28 (74%) 31 (65%) 27 (66%) 
Number of Subjects Analysis 
by Time point 
FOR:  IgM 
Treatment Group 
Placebo 
(N=38) 
OCA 
10 mg  
(N=38) 
OCA 
25 mg  
(N=48) 
OCA 
50 mg 
(N=41) 
Baseline 32 35 41 35 
Day 85/ET 33 29 38 31 
Change from baseline 30 (79%) 28 (74%) 33 (69%) 28 (68%) 
Number of Subjects Analysis 
by Time point 
FOR:  FGF19/Total BA 
Treatment Group 
Placebo 
(N=38) 
OCA 
10 mg  
(N=38) 
OCA 
25 mg  
(N=48) 
OCA 
50 mg 
(N=41) 
Baseline 32 32 42 34 
Day 85/ET 35 29 40 33 
Change from baseline 30 (79%) 26 (68%) 38 (79%) 30 (73%) 
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Supplementary Table 7.  Patient Disposition in the Open-label Extension Trial. 
 
Reason for Discontinuation 
Number of Patients 
(N=78) 
Pruritus 10 (13%) 
Other Adverse Event 3 (4%) 
Increased Conjugated Bilirubin 1 (1%) 
Protocol Violation 1 (1%) 
Withdrew Consent/Lost 2 (3%) 
Other 2 (3%) 
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Supplementary Table 8.  Incidence of All Adverse Events Occurring in ≥5% in Any Treatment 
Group in the Open-label Extension Trial. 
 
Adverse Event 
Number of Patients 
(N=78) 
Pruritus 68 (87%) 
Fatigue 10 (13%) 
Insomnia 10 (13%) 
Upper Respiratory Tract Infection 10 (13%) 
Headache 8 (10%) 
Rash 8 (10%) 
Constipation 7 (9%) 
Abdominal distension    6 (8%) 
Nausea    4 (5%) 
Edema Peripheral 5 (6%) 
Nasopharygitis 7 (9%) 
Sinusitis 5 (6%) 
Excoriation 6 (8%) 
Arthralgia 5 (6%) 
Pain in extremity 5 (6%) 
Nasal Congestion  4 (5%) 
Ecchymosis  5 (6%) 
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